"4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile"@en . "Food increase the exposure of bosutinib. Tmax, single dose, cancer patients, fed-state = 4-6 hours; After 15 daily doses of bosutinib 500 mg with food in CML patients, the pharmacokinetic parameters are as follows: Cmax = 200 ng/mL; AUC = 3650 ng\u2219h/mL "@en . . "Bosutinib Monohydrate"@en . "Bosutinib"@en . . "380843-75-4"@en . "SKI-606"@en . . . . . . . . . . . . . "Bosutinib"@en . . . . . "Bosulif\u00AE"@en . "Mean clearance (CL/F), single oral dose, fed-state = 189 L/h "@en . . . "Bosutinib is a tyrosine kinase inhibitor. Although it is able to inhibit several tyrosine kinases such as Src, Lyn, and Hck, which are members of the Src-family of kinases, its primary target is the Bcr-Abl kinase. The Bcr-Abl gene is a chimeric oncogene created from the fusion of the breakpoint-cluster (Bcr) gene and Abelson (Abl) tyrosine gene. This chromosomal abnormality results in the formation of what is commonly known as the Philadelphia chromosome or Philadelphia translocation. The Bcr-Abl gene expresses a particular kinase that promotes the progression of CML. A decrease in the growth and size of the CML tumour has been observed following administration of bosutinib. Bosutinib did not inhibit the T315I and V299L mutant cells. "@en . . . . . "Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue. Because bosutinib is not an inhibitor of c-KIT or PDGF receptor, it has less hematologic toxicities. "@en . "Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients. "@en . . . . "Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours "@en . . . . "Apparent volume of distribution = 6080 \u00B1 1230 L."@en . "# http://en.wikipedia.org/wiki/Philadelphia_chromosome # FDA label # Amsberg GK, Schafhausen P: Bosutinib in the management of chronic myelogenous leukemia. Biologics. 2013;7:115-22. doi: 10.2147/BTT.S30182. Epub 2013 May 6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/23674887 # Keller-V Amsberg G, Brummendorf TH: Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia. Expert Rev Anticancer Ther. 2012 Sep;12(9):1121-7. doi: 10.1586/era.12.84. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/23098112"@en . "When given with a high fat meal, the Cmax and AUC of bosutinib increased 1.8- and 1.7-fold, respectively."@en . . "Humans and other mammals"@en . "94% bound to human plasma proteins in vitro. 96% bound to human plasma proteins in healthy subjects ex vivo. Extent of protein binding is not concentration-dependent. "@en . . "Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012. "@en . "SKI 606"@en . . "approved"@en . . . . . . . . "When given a single oral dose, 91.3% of the dose was recovered in feces and 3% of the dose recovered in urine. "@en . . . . . . .